Data / Drug companies / Venlafaxine
Venlafaxine: 33 companies and 116 products in the FDA NDC directory
Venlafaxine is listed in the FDA National Drug Code Directory by 33 companies, with 116 products in commercial distribution. 115 of the products (99.1%) are marketed under an abbreviated new drug application (ANDA), the generic route. The most common dosage forms are tablet; tablet, extended release; tablet, coated, and the newest product started marketing on October 19, 2026.
SpecStream is the live web data engine for teams and agents. It reads the National Drug Code Directory that FDA publishes, and this page is that reading. Ask for the companies that make a drug, a class or a dosage form, with their headquarters, website and size added from the web, and new listings and discontinued products arrive in your sheet, CRM, Slack or agent as FDA posts them.
- Companies listing it
- 33
- Products
- 116
- Generic (ANDA) products
- 115 (99.1%)
- Application numbers
- 13
- Routes
- Oral
- openFDA record search
- api.fda.gov
Companies that list venlafaxine
Ranked by number of products. Finished drugs in commercial distribution.
| Company | Products | Main dosage forms | Main marketing category | Newest product started |
|---|---|---|---|---|
| BluePoint Laboratories | 9 | tablet; tablet, extended release | Generic drugs (ANDA) | April 30, 2021 |
| Cadila Pharmaceuticals Limited | 8 | tablet; tablet, coated | Generic drugs (ANDA) | December 3, 2018 |
| Remedyrepack Inc. | 6 | tablet, extended release; tablet | Generic drugs (ANDA) | October 19, 2026 |
| Alembic Pharmaceuticals Inc. | 5 | tablet | Generic drugs (ANDA) | October 1, 2015 |
| Alembic Pharmaceuticals Limited | 5 | tablet | Generic drugs (ANDA) | October 1, 2015 |
| Golden State Medical Supply, Inc. | 5 | tablet | Generic drugs (ANDA) | June 13, 2008 |
| Heritage Pharmaceuticals Inc. D/B/A Avet Pharmaceuticals Inc. | 5 | tablet | Generic drugs (ANDA) | July 19, 2021 |
| NuCare Pharmaceuticals,Inc. | 5 | tablet | Generic drugs (ANDA) | October 1, 2015 |
| Sun Pharmaceutical Industries, Inc. | 5 | tablet | Generic drugs (ANDA) | June 13, 2008 |
| Zydus Pharmaceuticals USA Inc. | 5 | tablet | Generic drugs (ANDA) | June 13, 2008 |
| Ajanta Pharma USA Inc. | 4 | tablet, extended release | Generic drugs (ANDA) | April 12, 2023 |
| Ascend Laboratories, LLC | 4 | tablet, extended release | Generic drugs (ANDA) | June 11, 2021 |
| Camber Pharmaceuticals, Inc. | 4 | tablet, extended release | Generic drugs (ANDA) | October 23, 2020 |
| Rising Pharma Holdings, Inc. | 4 | tablet, extended release | Generic drugs (ANDA) | November 28, 2022 |
| XLCare Pharmaceuticals, Inc. | 4 | tablet, extended release | Generic drugs (ANDA) | February 26, 2021 |
| Zydus Lifesciences Limited | 4 | tablet, extended release | Generic drugs (ANDA) | September 1, 2022 |
| Zydus Pharmaceuticals USA Inc. | 4 | tablet, extended release | Generic drugs (ANDA) | September 1, 2022 |
| A-S Medication Solutions | 3 | tablet | Generic drugs (ANDA) | October 1, 2015 |
| American Health Packaging | 3 | tablet | Generic drugs (ANDA) | September 29, 2015 |
| Bryant Ranch Prepack | 3 | tablet | Generic drugs (ANDA) | October 1, 2015 |
| Modavar Pharmaceuticals LLC | 3 | tablet, coated | Generic drugs (ANDA) | January 5, 2018 |
| Proficient Rx LP | 3 | tablet | Generic drugs (ANDA) | October 1, 2015 |
| Coupler LLC | 2 | tablet | Generic drugs (ANDA) | June 8, 2026 |
| Dr. Reddy's Laboratories Inc. | 2 | tablet, extended release | Generic drugs (ANDA) | September 20, 2021 |
| Northwind Health Company, LLC | 2 | tablet | Generic drugs (ANDA) | June 10, 2021 |
| St. Mary's Medical Park Pharmacy | 2 | tablet | Generic drugs (ANDA) | April 21, 2023 |
| Almatica Pharma LLC | 1 | tablet, extended release | New drug applications (NDA) | June 30, 2022 |
| Aphena Pharma Solutions - Tennessee, LLC | 1 | tablet | Generic drugs (ANDA) | June 13, 2008 |
| Bryant Ranch Prepack | 1 | tablet | Generic drugs (ANDA) | June 13, 2008 |
| NCS HealthCare of Ky, LLC DBA Vangard Labs | 1 | tablet | Generic drugs (ANDA) | June 13, 2008 |
| PD-Rx Pharmaceuticals, Inc. | 1 | tablet | Generic drugs (ANDA) | June 13, 2008 |
| Preferred Pharmaceuticals Inc. | 1 | tablet, extended release | Generic drugs (ANDA) | February 10, 2025 |
| Proficient Rx LP | 1 | tablet | Generic drugs (ANDA) | October 1, 2015 |
Dosage forms
| Dosage form | Products | Share |
|---|---|---|
| Tablet | 70 | 60.3% |
| Tablet, extended release | 40 | 34.5% |
| Tablet, coated | 6 | 5.2% |
Marketing categories
| Marketing category | Products | Share |
|---|---|---|
| Generic drugs (ANDA) | 115 | 99.1% |
| New drug applications (NDA) | 1 | 0.9% |
Pharmacologic classes
| Class | Products |
|---|---|
| Serotonin and Norepinephrine Reuptake Inhibitor | 116 |
Updated November 6, 2026. Read from US Food and Drug Administration, National Drug Code Directory (openFDA). CC0 1.0 public domain dedication (openFDA). Counts are products in the FDA National Drug Code Directory on November 6, 2026: 138,262 products in commercial distribution, meaning without a marketing end date in the past. A company is a labeler code; one company can hold several codes, and the directory carries no address. Inclusion in the directory is not FDA approval, and the marketing category says under which kind of application or rule a product is sold. This page uses openFDA data and is not endorsed or certified by FDA. Free to reuse with credit to SpecStream under CC BY 4.0. Spot a wrong value? Write to [email protected] with the link to this page.